These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31330134)

  • 21. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis.
    Parafati M; Kirby RJ; Khorasanizadeh S; Rastinejad F; Malany S
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30254132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver.
    Canivet CM; Bonnafous S; Rousseau D; Leclere PS; Lacas-Gervais S; Patouraux S; Sans A; Luci C; Bailly-Maitre B; Iannelli A; Tran A; Anty R; Gual P
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165705. PubMed ID: 32001301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the effect of a mixture of two main conjugated linoleic acid isomers on hepatic steatosis in HepG2 cellular model.
    Jalilian A; Golmohammadi T; Meshkani R; Koushki M; Eivazi N; Khorzoughi RB; Fard SRH; Paknejad M
    Mol Biol Rep; 2021 Feb; 48(2):1359-1370. PubMed ID: 33580458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silencing of STE20-type kinase TAOK1 confers protection against hepatocellular lipotoxicity through metabolic rewiring.
    Xia Y; Andersson E; Anand SK; Cansby E; Caputo M; Kumari S; Porosk R; Kilk K; Nair S; Marschall HU; Blüher M; Mahlapuu M
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36930872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease.
    Breher-Esch S; Sahini N; Trincone A; Wallstab C; Borlak J
    BMC Med Genomics; 2018 Dec; 11(1):111. PubMed ID: 30547786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. β-Klotho gene variation is associated with liver damage in children with NAFLD.
    Dongiovanni P; Crudele A; Panera N; Romito I; Meroni M; De Stefanis C; Palma A; Comparcola D; Fracanzani AL; Miele L; Valenti L; Nobili V; Alisi A
    J Hepatol; 2020 Mar; 72(3):411-419. PubMed ID: 31655133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro.
    Mahli A; Seitz T; Beckröge T; Freese K; Thasler WE; Benkert M; Dietrich P; Weiskirchen R; Bosserhoff A; Hellerbrand C
    Cells; 2019 May; 8(5):. PubMed ID: 31096638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK; Dai W; Zheng YW; Zhao SP
    Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1).
    Chen M; Drury JE; Penning TM
    Steroids; 2011 Apr; 76(5):484-90. PubMed ID: 21255593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD.
    Huang KT; Chen KD; Hsu LW; Kung CP; Li SR; Chen CC; Chiu KW; Goto S; Chen CL
    Nutrients; 2020 Jan; 12(1):. PubMed ID: 31968655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes.
    Latorre J; Ortega FJ; Liñares-Pose L; Moreno-Navarrete JM; Lluch A; Comas F; Oliveras-Cañellas N; Ricart W; Höring M; Zhou Y; Liebisch G; Nidhina Haridas PA; Olkkonen VM; López M; Fernández-Real JM
    EBioMedicine; 2020 Mar; 53():102697. PubMed ID: 32143184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition.
    Patankar JV; Wong CK; Morampudi V; Gibson WT; Vallance B; Ioannou GN; Hayden MR
    Am J Physiol Endocrinol Metab; 2018 May; 314(5):E418-E432. PubMed ID: 29066462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease.
    Sciarrillo CM; Keirns BH; Koemel NA; Anderson KL; Emerson SR
    Liver Int; 2021 May; 41(5):894-904. PubMed ID: 33506572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth hormone ameliorates high glucose-induced steatosis on in vitro cultured human HepG2 hepatocytes by inhibiting de novo lipogenesis via ChREBP and FAS suppression.
    Villanueva-Ortega E; Méndez-García LA; Garibay-Nieto GN; Laresgoiti-Servitje E; Medina-Bravo P; Olivos-García A; Muñoz-Ortega MH; Ventura-Juárez J; Escobedo G
    Growth Horm IGF Res; 2020; 53-54():101332. PubMed ID: 32698101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis.
    Siculella L; Tocci R; Rochira A; Testini M; Gnoni A; Damiano F
    Biochim Biophys Acta; 2016 May; 1861(5):471-81. PubMed ID: 26869449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of lipid metabolism in a novel immortalized human hepatocyte cell line.
    Green CJ; Johnson D; Amin HD; Sivathondan P; Silva MA; Wang LM; Stevanato L; McNeil CA; Miljan EA; Sinden JD; Morten KJ; Hodson L
    Am J Physiol Endocrinol Metab; 2015 Sep; 309(6):E511-22. PubMed ID: 26126685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.